Abstract
This paper highlights the characteristic features of the Japanese good clinical practice and the Japanese clinical trial system. It also discusses the ongoing reform of the system, including the revision of the Pharmaceutical Affairs Law and substitute ordinances.
Get full access to this article
View all access options for this article.